Brixton Biosciences is developing Neural Ice™, a therapeutic injection designed to provide three months or more of pain relief for patients suffering from chronic and acute pain. This investigational treatment, developed at Massachusetts General Hospital, aims to address the significant unmet clinical need for effective pain management solutions.
Funding
$41M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NIFounders
Product
Problem
Chronic and acute pain management often relies on short-term solutions, leaving a significant unmet need for longer-lasting pain relief options. Current treatments may require frequent administration or have limited efficacy, impacting patients' quality of life.
Solution
Brixton Biosciences is developing Neural Ice™, an investigational therapeutic injection designed to provide extended pain relief, potentially lasting three months or more, from a single administration. Developed at Massachusetts General Hospital, Neural Ice™ aims to address the need for effective and durable pain management. The treatment is currently undergoing clinical research to measure its safety and efficacy in managing both acute and chronic pain conditions.
Target Audience
The primary target audience includes patients suffering from chronic and acute pain, as well as healthcare providers seeking longer-lasting and more effective pain management solutions.
Features
- Investigational therapeutic injection for pain management
- Designed to provide pain relief for three months or longer
- Developed at Massachusetts General Hospital
- Potential application for both acute and chronic pain conditions
- Currently undergoing first-in-human clinical trials